Design and synthesis of a potent and selective triazolone-based peroxisome proliferator-activated receptor α agonist

…, J Osborne, C Montrose-Rafizadeh…

文献索引：Xu, Yanping; Mayhugh, Daniel; Saeed, Ashraf; Wang, Xiaodong; Thompson, Richard C.; Dominianni, Samuel J.; Kauffman, Raymond F.; Singh, Jaipal; Bean, James S.; Bensch, William R.; Barr, Robert J.; Osborne, John; Montrose-Rafizadeh, Chahrzad; Zink, Richard W.; Yumibe, Nathan P.; Huang, Naijia; Luffer-Atlas, Debra; Rungta, Deepa; Maise, Dale E.; Mantlo, Nathan B. Journal of Medicinal Chemistry, 2003 , vol. 46, # 24 p. 5121 - 5124

全文：HTML全文

被引用次数: 76

摘要

For several years, the fibrates (Figure 1, eg, fenofibrate, 1) have been broadly utilized for the clinical treatment of dyslipidemia and remain the current treatment of choice for patients with severe hypertriglyceridemia. 10,11 These agents can effectively decrease serum triglycerides and elicit increases in HDL-cholesterol concentrations in humans. 10 Several studies have provided evidence that the hypolipidemic effect of this class of drugs is caused by their agonist at ...